



JPW

PATENT
Attorney Docket No. 056707-5001-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gregory M. Glenn <i>et al.</i>)	
)	
Application No. 10/790,715)	Group Art Unit: 1645
)	
Filed: March 3, 2004)	Examiner: Not Assigned
)	
For: Use of Penetration Enhancers and Barrier)	
Disruption Agents to Enhance the)	
Transcutaneous Immune Response)	
Induced by ADP-Ribosylating Exotoxin)	

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, **Mail Stop Amendment**
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

The present application is a continuation application of U.S. Application 09/257,188, now U.S. Patent No. 6,797,276, issued September 28, 2004. Copies of documents listed on pages 1-14 have previously been submitted in U.S. Application 09/257,188. The Examiner's attention is respectfully directed to the art of record in this prior application and thus these references are not being submitted.

Copies of documents Y1-Y42 and Y89-Y91, U.S. patent documents, are not attached. However, copies of documents Y43-Y88 and Y92-Y100 are attached along with a copy of the European Search Report which issued in a corresponding European application, European Patent Application No. EP 03 00 7948.7. Applicants respectfully request that the Examiner consider

BEST AVAILABLE COPY

the listed documents and evidence that consideration by making appropriate notations on the attached forms.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies a document as "prior art" against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Dated: **October 13, 2004**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004
Telephone: (202) 739-3000
Facsimile: (202)-739-3001

Respectfully submitted,
Morgan, Lewis & Bockius LLP



Erich E. Veitenheimer
Registration No. 40,420



Atty.
Dkt. No.

Applicant Ref.	056707-5001-01
----------------	----------------

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit: 1645

Page 1 of 14

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	aa 3,837,340	09/1974	COUNTER			
	ab 3,948,263	04/1976	DRAKE			
	ac 3,982,536	09/1976	KROGSENG			
	ad 4,196,191	04/1980	ALMEIDA			
	ae 4,220,584	09/1980	LIMJUCO			
	af 4,235,871	11/1980	PAPAHADJOPOULOS			
	ag 4,285,931	08/1981	LIMJUCO			
	ah 4,394,448	07/1983	SZOKA			
	ai 4,411,888	10/1983	KLIPSTEIN			
	aj 4,455,142	06/1984	MARTINS			
	ak 4,484,923	11/1984	AMKRAUT			
	al 4,497,796	02/1985	SALSER			
	am 4,587,044	05/1986	MILLER			
	an 4,692,462	09/1987	BANERJEE			
	ao 4,725,271	02/1988	KOROL			
	ap 4,732,892	03/1988	SARPOTDAR			
	aq 4,743,588	05/1988	MIREJOVSKY			
	ar 4,761,372	08/1988	MAAS			
	as 4,764,381	08/1988	BODOR			
	at 4,783,450	11/1988	FAWZI			
	au 4,834,985	05/1989	ELGER			
	av 4,876,278	10/1989	TAYLOR			
	aw 4,877,612	10/1989	BERGER			
	ax 4,892,737	01/1990	BODOR			
	ay 4,908,389	03/1990	MAHJOUR			
	az 4,917,688	04/1990	NELSON			

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No

OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

--	--

Examiner _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PM&S FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

056707-5001-01

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Page 2 of 14

Examiner: Not Assigned Group Art Unit: 1645

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	ba	4,917,895	04/1990	LEE			
	bb	4,921,757	05/1990	WHEATLEY			
	bc	4,929,442	05/1990	POWELL			
	bd	4,946,853	08/1990	BANNON			
	be	4,956,171	09/1990	CHANG			
	bf	4,960,771	10/1990	RAJADHYAKSHA			
	bg	4,970,206	11/1990	ALEXANDER			
	bh	5,008,050	04/1991	CULLIS			
	bi	5,008,111	04/1991	BODOR			
	bj	5,023,252	06/1991	HSIEH			
	bk	5,028,435	07/1991	KATZ			
	bl	5,030,629	07/1991	RAJADHYAKSHA			
	bm	5,032,402	07/1991	DIGENIS			
	bri	5,041,439	08/1991	KASTING			
	bo	5,045,317	09/1991	CHESS			
	bp	5,049,386	09/1991	EPPSTEIN			
	bq	5,049,387	09/1991	AMKRAUT			
	br	5,059,189	10/1991	CILENTO			
	bs	5,059,421	10/1991	LOUGHREY			
	bt	5,069,904	12/1991	MASTERSON			
	bu	5,082,866	01/1992	WONG			
	bw	5,108,921	04/1992	LOW			
	bv	5,142,044	08/1992	MINASKANIAN			
	bx	5,162,315	11/1992	RAJADHYAKSHA			
	by	5,164,406	11/1992	HELMAN			

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
								Enclosed	No
								Enclose	No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PM&S FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#	Client Ref
----	------------

056707-5001-01

Applicants: GLENN et al.

Appln. No: 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assigned Group Art Unit: 1645

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 3 of 14

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
ca	5,166,320	11/1992	WU			
cb	5,169,637	12/1982	LENK			
cc	5,182,109	01/1993	TAMURA			
cd	5,196,410	03/1993	FRANCOEUR			
ce	5,200,393	04/1993	WEINER			
cf	5,204,339	04/1993	MINASKANIAN			
cg	5,215,520	06/1993	SHROOT			
ch	5,225,182	07/1993	SHARMA			
ci	5,232,935	08/1993	COLAS			
cj	5,234,959	08/1993	MINASKANIAN			
ck	5,238,944	08/1993	WICK			
cl	5,240,846	08/1993	COLLINS			
cm	5,252,334	10/1993	CHIANG			
cn	5,256,422	10/1993	ALBERT			
co	5,260,066	11/1993	WOOD			
cp	5,270,346	12/1993	MINASKANIAN			
cq	5,308,835	05/1994	CLEMENTS			
cr	5,326,566	07/1994	PARAB			
cs	5,326,790	07/1994	THORNFELDT			
ct	5,328,470	07/1994	NABEL			
cu	5,332,576	07/1994	MANTELLE			
cv	5,332,577	07/1994	GERTNER			
cw	5,340,588	08/1994	DOMB			
cx	5,352,449	10/1994	BELTZ			
cy	5,399,346	03/1995	ANDERSON			
cz	5,411,738	05/1995	HIND			

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty.
Dkt. No.



056707-5001-01

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicants: GLENN et al.

Appln. No.: 10/790,715

Filing Date: March 3, 2004

Page 4 of 14

Examiner: Not Assgn. Group Art Unit: 1645

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	da	5,428,132	06/1995	HIRSCH		
	db	5,445,611	08/1995	EPPSTEIN		
	dc	5,458,140	10/1995	EPPSTEIN		
	dd	5,462,743	10/1995	TURNER		
	de	5,464,386	11/1995	HOFMANN		
	df	5,472,946	12/1995	PECK		
	dg	5,482,965	01/1996	RAJADHYAKSHA		
	dh	5,492,698	02/1996	VON KLEINSORGEN		
	di	5,505,956	04/1996	KIM		
	dj	5,505,958	04/1996	BELLO		
	dk	5,533,995	07/1996	CORISH		
	dl	5,534,260	07/1996	PETERSEN		
	dm	5,536,263	07/1996	ROLF		
	dn	5,540,931	07/1996	HEWITT		
	do	5,547,932	08/1996	CURIEL		
	dp	5,573,778	11/1996	THERRIALT		
	dq	5,578,475	11/1996	JESSEE		
	dr	5,580,859	12/1996	FELGNER		
	ds	5,589,466	12/1996	FELGNER		
	dt	5,593,972	01/1997	WEINER		
	du	5,601,827	02/1997	COLLIER		
	dv	5,607,691	03/1997	HALE		
	dw	5,612,382	03/1997	FIKE		
	dx	5,614,212	03/1997	D'ANGELO		
	dy	5,614,503	03/1997	CHAUDHARY		
	dz	5,620,896	04/1997	HERMANN		

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	Abstract		Readily Available	
								Enclosed	No	Enclose	No

OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.):

--	--

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PM&S FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#	Client Ref.
056707-5001-01	

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Page 5 of 14

Examiner: Not Assigned Group Art Unit: 1645

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
ea	5,626,866	05/1997	EBERT			
eb	5,643,578	07/1997	ROBINSON			
ec	5,658,587	08/1997	SANTUS			
ed	5,661,025	08/1997	SZOKA			
ee	5,661,130	08/1997	MEEZAN			
ef	5,674,503	10/1997	OLAFSON			
eg	5,676,954	10/1997	BRIGHAM			
eh	5,679,647	10/1997	CARSON			
ei	5,686,100	11/1997	WILLE			
ej	5,693,024	12/1997	FLOWER			
ek	5,693,622	12/1997	WOLFF			
el	5,695,991	12/1997	LINDHOLM			
em	5,697,901	12/1997	ERIKSSON			
en	5,698,416	12/1997	WOLF			
ep	5,703,057	12/1997	JOHNSTON			
ep	5,705,151	01/1998	DOW			
eq	5,718,914	02/1998	FOLDVARI			
er	5,720,948	02/1998	BRUCKS			
es	5,722,397	03/1998	EPPSTEIN			
et	5,723,114	03/1998	THORNFELDT			
eu	5,731,303	03/1998	HSIEH			
ev	5,733,572	03/1998	UNGER			
ew	5,733,762	03/1998	MIDOUX			
ex	5,736,154	04/1998	FUISZ			
ey	5,736,392	04/1998	HAWLEY-NELSON			
ez	5,736,524	04/1998	CONTENT			

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PM&S FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

056707-5001-01

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Page 6 of 14

Examiner: Not Assigned Group Art Unit: 1645

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	fa 5,738,647	04/1998	BERNHARD			
	fb 5,739,118	04/1998	CARRANO			
	fc 5,741,510	04/1998	ROLF			
	fd 5,756,117	05/1998	D'ANGELO			
	fe 5,760,096	06/1998	THORNFELDT			
	ff 5,766,899	06/1998	KUO			
	fg 5,770,580	06/1998	LEDLEY			
	fh 5,773,022	06/1998	NYQVIST-MAYER			
	fi 5,780,050	07/1998	JAIN			
	fj 5,783,567	07/1998	HEDLEY			
	fk 5,789,230	08/1998	COTTON			
	fl 5,804,214	09/1998	WONG			
	fm 5,804,566	09/1998	CARSON			
	fn 5,811,406	09/1998	SZOKA			
	fo 5,814,599	09/1998	MITRAGOTRI			
	fp 5,814,617	09/1998	HOFFMAN			
	fq 5,824,538	10/1998	BRANSTROM			
	fr 5,827,703	10/1998	DEBS			
	fs 5,827,705	10/1998	DEAN			
	ft 5,830,876	11/1998	WEINER			
	fu 5,830,877	11/1998	CARSON			
	fv 5,834,010	11/1998	QUAN			
	fw 5,837,289	11/1998	GRASELA			
	fx 5,837,533	11/1998	BOUTIN			
	fy 5,840,059	11/1998	MARCH			
	fz 5,843,913	12/1998	LI			

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PM&S FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

056707-5001-01

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Page 7 of 14

Examiner: Not Assign. Group Art Unit: 1645

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	ga 5,844,107	12/1998	HANSON			
	gb 5,846,540	12/1998	RESTIFO			
	gc 5,846,949	12/1998	WAGNER			
	gd 5,849,719	12/1998	CARSON			
	ge 5,853,751	12/1998	MASIZ			
	gf 5,856,187	01/1999	RESTIFO			
	gg 5,858,784	01/1999	DEBS			
	gh 5,866,553	02/1999	DONNELLY			
	gi 5,877,159	03/1999	POWELL			
	gj 5,877,302	03/1999	HANSON			
	gk 5,885,971	03/1999	GERMAN			
	gl 5,910,306	06/1999	ALVING			
	gm 5,910,488	06/1999	NABEL			
	gn 5,914,114	06/1999	CASSELS			
	go 5,916,879	06/1999	WEBSTER			
	gp 5,935,838	08/1999	ASKELOEF			
	gq 5,961,979	10/1999	SRIVASTAVA			
	gr 5,980,898	11/1999	GLENN			
	gs 5,985,847	11/1999	CARSON			
	gt 6,008,200	12/1999	KRIEG			
	gu 6,039,969	03/2000	TOMAI			
	gv 6,087,341	07/2000	KHAVARI			
	gw 6,173,202	01/2001	EPPSTEIN			
	gx 6,180,136	01/2001	LARSON			
	gy 6,183,434	02/2001	EPPSTEIN			
	gz 6,210,672	04/2001	COWING			

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed	No
						Enclose	No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Page 8 of 14

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)

[illegible]

OTHER: (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty. Dkt. No.	M#	Client Ref.
	056707-5001-01	

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicants: GLENN et al.	
Appl. No. 10/790,715	
Filing Date: March 3, 2004	
Examiner: Not Assigned	Group Art Unit: 1645

Page 9 of 14

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	Abstract		Readily Available	
								Enclosed	No	Enclose	No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

ia	ALLISON "Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding" Arch Biochem Biophys 365 (1999) 289-298
ib	ALLISON "Optimization of storage stability of lyophilized actin using combinations of disaccharides and dextran" J Pharm Sci 89 (2000) 199-214
ic	ANDYA "The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody" Pharm Res 16 (1999) 350-358
id	ARAKAWA "Protein-solvent interactions in pharmaceutical formulations" Pharma Res 8 (1991) 285-291
ie	ARANY "Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (imiquimod) in genital warts" Antimicrob Agents Chemother 44 (2000) 1869-1873
if	ALVING "Effectiveness of liposomes as potential carriers of vaccines: Applications to cholera toxin and human malaria sporozoite antigen" Vaccine 4 (1986) 166-172
ig	ALVING "Liposomes as carriers of antigens and adjuvants" J Immunol Methods 140 (1991) 1-13
ih	ALVING "Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants" Immunobiology 187 (1993) 430-446
ii	ALVING "Novel adjuvant strategies for experimental malaria and AIDS vaccines" Ann NY Acad Sci 690 (1993) 265-275
ij	ALVING "The preparation and use of liposomes in immunological studies" In: <i>Liposome Technology</i> , vol. 3, CRC Press (1993) pp. 317-343
ik	ALVING "Cytotoxic T lymphocytes induced by liposomal antigens: Mechanisms of immunological presentation" AIDS Res Hum Retroviruses 10 suppl 2 (1994) S91-S94
il	ALVING "Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides" Immunol Rev 145 (1995) 5-31
im	BECKER "Mechanism in allergic contact dermatitis" Exp Dermatol 2 (1993) 63-69
in	BIRCH "Trehaloses" Adv Carb Chem Biochem 18 (1963) 201-2225
io	BLAUVELT "Human Langerhans cells express E-cadherin" J Invest Dermatol 104 (1995) 293-296
ip	BOS "The 500 dalton rule for the skin penetration of chemical compounds and drugs" Exp Dermatol 9 (2000) 165-169

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Atty. Dkt. No.	M#	Client Ref.
	056707-5001-01	

**INFORMATION DISCLOSURE STATEMENT
 BY APPLICANT**

Page 10 of 14

Applicants: GLENN et al.

Appln. No. 10/790,715

Filing Date: March 3, 2004

Examiner: Not Assig. Group Art Unit: 1645

U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS							English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	Enclosed	No	Enclose	No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.):

ja	BOVSUN "DNA vaccine rubbed on skin provokes immune response" Biotechnol Newswatch (September 20, 1999) page 4									
jb	BOWEN "Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens" Immunol 81 (1994) 338-342									
jc	BUATES "Treatment of experimental Leishmaniasis with the immunomodulators imiquimod and S-28463: Efficacy and mode of action" J Infect Dis 179 (1999) 1485-1494									
jd	CHEN "Induction of systemic immune responses in sheep by topical application of cholera toxin to skin" Vet Immunol Immunopathol 77 (2000) 191-199									
je	CHIN "Antibody response against Pseudomonas aeruginosa membrane proteins in experimentally infected sheep" Vet Microbiol 43 (1995) 21-32									
jf	CHIN "Manipulating systemic and mucosal immune responses with skin-deliverable adjuvants" J Biotechnol 44 (1996) 13-19									
gg	CONDON "DNA-based immunization by in vivo transfection of dendritic cells" Nature Med 2 (1996) 1122-1128									
jh	COSTANTINO "Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone" J Pharm Sci 87 (1998) 1412-1420									
ji	CRAIG "Cutaneous responses to cholera skin toxin in man. I. Responses in unimmunized American males" J Infect Dis 125 (1972) 203-215									
jj	DE HAAN "Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice" Vaccine 13 (1995) 1320-1324									
jk	EGBARIA "Liposomes as topical drug delivery system" Adv Drug Delivery Rev 5 (1990) 287-300									
jl	ENK "An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune responses in skin" J Immunol 151 (1993) 2390-2398									
jm	FAN "Immunization via hair follicles by topical application of naked DNA to normal skin" Nature Biotechnol 17 (1999) 870-872									
jn	FLEISHER "Topical delivery of growth hormone releasing peptide using liposomal systems: An in vitro study using hairless mouse skin" Life Sci 57 (1995) 1293-1297									
jo	FRANK "Long-term stabilization of biologicals" Bio/Technology 12 (1994) 253-256									

Examiner	Date Considered:
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>	

Atty. Dkt. No.	M#	Client Ref.
	056707-5001-01	

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicants: GLENN et al.	
Appln. No. 10/790,715	
Filing Date: March 3, 2004	
Examiner: Not Assigned	Group Art Unit: 1645

Page 11 Of 14

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed No	Enclose No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

ka	GEKKO "Mechanism of protein stabilization by glycerol: Preferential hydration in glycerol-water mixtures" Biochemistry 20 (1981) 4667-4676
kb	GLENN "Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A" Immunol Lett 47 (1995) 73-78
kc	GLENN "Skin immunization made possible by cholera toxin" Nature 391 (1998) 851
kd	GLENN "Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge" J Immunol 161 (1998) 3211-3214
ke	GLENN "Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants" Infect Immun 67 (1999) 1100-1106
kf	GLENN "Transcutaneous immunisation" Exp Opin Invest Drugs 8 (1999) 797-805
kg	GLENN "Transcutaneous immunization" In: <i>The Jordan Report 2000</i> , NIAID, pp. 91-93
kh	GLENN "Transcutaneous immunization: A human vaccine delivery strategy using a patch" Nature Med 6 (2000) 1403-1406
ki	GLENN "Transcutaneous immunization" In: <i>Vaccine Adjuvants</i> , Humana Press (April 2000) pp. 315-326
kj	GLENN "Transcutaneous immunization" In: <i>New Vaccine Technologies</i> , Landes Biosciences (June 2001) pp. 292-304
kk	GOODNOW "Chance encounters and organized rendezvous" Immunol Rev 156 (1997) 5-10
kl	GUPTA "Adjuvants for human vaccines - current status, problems and future prospects" Vaccine 13 (1995) 1263-1276
km	HAMMOND "Transcutaneous immunization of domestic animals: Opportunities and challenges" Adv Drug Delivery Rev 43 (2000) 45-55
kn	HAMMOND "Transcutaneous immunization: T cell responses and boosting of existing immunity" Vaccine 19 (2001) 2701-2707
ko	HANSON "Introduction to formulation of protein pharmaceuticals" In: <i>Stability of Protein Pharmaceuticals</i> , Plenum (1992) pp. 209-233
kp	HOELZLE "Increased accumulation of trehalose in rhizobia cultured under 1% oxygen" Appl Environ Microbiol 56 (1990) 3213-3215

Examiner

Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Page 12 Of 14

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

FOREIGN PATENT DOCUMENTS								English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	Enclosed	No	Enclose	No

	1a	HSIUNG <i>Diagnostic Virology 3rd Ed.</i> , Yale Univ. Press (1982) pp. 29-34
	1b	IIZUKA "Two simple methods for the evaluation of topically active anti-inflammatory steroidal ointments" <i>Agents Actions</i> 11 (1981) 254-259
	1c	IZUTSU "Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices" <i>Pharm.Res</i> 12 (1995) 838-843
	1d	JOHNSON "Vaccination onto bare skin" <i>Nature</i> 388 (1997) 729-730
	1e	KAHAN "Immunosuppressive therapy" <i>Current Opin Immunol</i> 4 (1992) 553-560
	1f	KNOP "Cellular and molecular mechanisms in the induction phase of contact sensitivity" <i>Intl Arch Allergy Immunol</i> 107 (1995) 231-232
	1g	KORTING "Topical liposome drugs to come: what the patent literature tells us" <i>J Am Acad Dermatol</i> 25 (1991) 1068-1071
	1h	KORTING "Interaction of liposomes with human epidermis reconstructed in vitro" <i>Br J Dermatol</i> 132 (1995) 571-579
	1i	KOSECKA "Pertussis toxin stimulates hypersensitivity and enhances nerve-mediated antigen uptake in rat intestines" <i>Am J Physiol</i> 267 (1994) G745-G752
	1j	LANE "In vitro-evaluation of human lymphocyte function" In: <i>Handbook of Experimental Immunology 4th Ed.</i> , vol. 2, Blackwell (1986) pp. 66.5-66.7
	1k	LUO "Synthetic DNA delivery systems" <i>Nature Biotechnol</i> 18 (2000) 33-37
	1l	MAHMOUD "Parasitic protozoa and helminths: Biological and immunological challenges" <i>Science</i> 246 (1989) 1015-1022
	1m	MARINARO "Mucosal effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4" <i>J Immunol</i> 155 (1995) 4621-4629
	1n	MENGIARDI "Virosomes as carriers for combined vaccines" <i>Vaccine</i> 13 (1995) 1306-1315
	1o	MEZEI "Liposomes - a selective drug delivery system for the topical route of administration. Lotion dosage form" <i>Life Sci</i> 26 (1980) 1473-1477
	1p	MOGHIMI "Current progress and future prospects of liposomes in dermal drug delivery" <i>J Microencapsul</i> 10 (1993) 155-162
	1q	NORIMATSU "Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine" <i>Vaccine</i> 13 (1995) 1325-1329

Date Considered:

30185091v1

Atty. Dkt. No.	M#	Client Ref.
	056707-5001-01	

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicants: GLENN et al.
Appln. No. 10/790,715
Filing Date: March 3, 2004
Examiner: Not Assigned Group Art Unit: 1645

Page 13 of 14

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
-------------------------	--------------------	-----------------	---	-------	--------------	---------------------------------

FOREIGN PATENT DOCUMENTS

Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	English Abstract	Translation Readily Available
						Enclosed No	Enclose No

OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

ma	PAUL "Transdermal immunization with large proteins by means of ultradeformable drug carriers" Eur J Immunol 25 (1995) 3521-3524
mb	PAUL "Noninvasive administration of protein antigens: Transdermal immunization with bovine serum albumin in transferosomes" Vaccine Res 4 (1995) 145-164
mc	PETERS "Dendritic cells: From ontogenetic orphans to myelo-monocytic descendants" Immunol Today 17 (1996) 273-278
md	POWERS "In previously immunized elderly adults inactivated influenza A (H1N1) virus vaccines induce poor antibody responses that are not enhanced by liposome adjuvant" Vaccine 13 (1995) 1330-1335
me	RANADE "Drug delivery systems. 6. Transdermal drug delivery" J Clin Pharmacol 31 (1991) 401-418
mf	RAO "Intracellular processing of liposome-encapsulated antigens by macrophages depends upon the antigen" Infect Immun 63 (1995) 2396-2402
mg	SANCHEZ "Formulation strategies for the stabilization of tetanus toxoid in poly(lactide-co-glycolide) microspheres" Intl J Pharm 185 (1999) 255-266
mh	SAUZET "Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides" Vaccine 13 (1995) 1339-1345
mi	SCHAEFER-KORTING "Liposome preparations: A step forward in topical drug therapy for skin disease?" J Am Acad Dermatol 21 (1989) 1271-1275
mj	SCHARTON-KERSTEN "Principles of transcutaneous immunization using cholera toxin as an adjuvant" Vaccine 17 suppl 2 (1999) S37-S43
mk	SCHARTON-KERSTEN "Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants" Infect Immun 68 (2000) 5306-5313
ml	SCHMITT "Bacterial toxins: Friends or foes" Emerging Infect Dis 5 (1999) 224-234
mm	SCHWARZENBERGER "Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ" J Invest Dermatol 106 (1996) 553-558
mn	SEO "Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis" Proc Natl Acad Sci USA 97 (2000) 371-376
mo	SMALL, In: <i>Handbook of Lipid Research</i> , Plenum, 4:43-87 and 89-96
mp	STACEY "Macrophages ingest and are activated by bacterial DNA" J Immunol 157 (1996) 2116-2122

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

Applicants: GLENN et al.
Appln. No. 10/790,715
Filing Date: March 3, 2004
Examiner: Not Assigned Group Art Unit: 1645

Page 14 of 14

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)				Class	Sub Class	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								English Abstract	Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name	Class	SubClass	Enclosed	No	Enclose	No

OTHER (Including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

na	STEINMAN "Dendritic cells in the T-cell areas of lymphoid organs" Immunol Rev 156 (1997) 25-37
nb	STINGL "The immune functions of epidermal cells" Immunol Ser 46 (1989) 3-72
nc	SUZUKI "Imiquimod, a topical immune response modifier, induces migration of Langerhans cells" J Invest Dermatol 114 (2000) 135-141
nd	UDEY "Cadherins and Langerhans cell immunobiology" Clin Exp Immunol 107 suppl 1 (1997) 6-8
ne	VASSELL "Activation of Langerhans cells following transcutaneous immunization" 13 FASEB J (1999) A633
nf	VERMA "Phagocytosis of liposomes by macrophages: intracellular fate of liposomal malaria antigen" Biochim Biophys Acta 1066 (1991) 229-238
ng	VERMA "Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages" Infect Immun 60 (1992) 2438-2444
nh	VUTLA "Transdermal iontophoretic delivery of enkephalin formulated in liposomes" J Pharm Sci 85 (1996) 5-8
ni	WALKER "The role of percutaneous penetration enhancers" Adv Drug Delivery Rev 18 (1996) 295-301
hj	WANG "Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine" J Immunol 154 (1995) 2784-2793
nk	WANG "Epicutaneous exposure of protein antigen induces a predominant Th2-like response with high IgE production in mice" J Immunol 156 (1996) 4077-4082
nl	WASSEF "Liposomes as carriers for vaccines" Immunomethods 4 (1994) 217-222
nm	WEINER "Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model" Antimicrob Agents Chemotherap 33 (1989) 1217-1221
nn	WHITE "Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes" Vaccine 11 (1993) 1341-1346
no	WHITE "Antibody and cytotoxic T-lymphocyte responses to a single liposome associated peptide antigen" Vaccine 13 (1995) 1111-1122
np	YASUTOMI "A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge" J Virol 69 (1995) 2279-2284
nq	ZELLMER "Interaction of phosphatidylcholine liposomes with the human stratum corneum" Biochim Biophys Acta 1237 (1995) 176-182

Date Considered:

30185091v1

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) PTO Form 1449				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
				Page 19 of 19			
				Applicants: Gregory M Glenn <i>et al</i> Filing Date: March 3, 2004		Group Art Unit: 1645	

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
	Y89	5,910,306	08/1999	Glenn			
	Y90	5,980,898	11/1999	Glenn			
	Y91	6,797,276	02/1999	Glenn			

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes No

OTHER DOCUMENTS		
	Y92	OCKENHOUSE "Sequestrin, a CD36 recognition protein on <i>Plasmodium falciparum</i> malaria-infected erythrocytes identified by anti-idiotypic antibodies" Proc Natl Acad Sci 88 (1991) 3175-3179
	Y93	OGRA "Vaccination strategies for mucosal immune responses" Clin Microbiol Rev 14 (2001) 430-445
	Y94	PODDA "The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine" Vaccine 19 (2001) 2673-2680
	Y95	WILLIAMS "Skin absorption enhancers" Critical Rev in Therapeutic Drug Carrier Systems 9 (1992) 305-353
	Y96	TAKIGAWA "Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis" Ann N Y Acad Sci 941 (2001) 139-146
	Y97	TANG "Vaccination onto bare skin" Nature 388 (1997) 729-730
	Y98	"Tuberculin, Purified protein Derivative, Tine Test" Physician's desk Reference, 3 pages (2001)
	Y99	WATABE "Protection against influenza virus challenge by topical application of influenza DNA vaccine" Vaccine 14 (2001) 4434-4444
Examiner: _____ Date Considered: _____		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) PTO Form 1449	Attorney Docket No. 056707-5001-01	Parent Application No. 10/790,715
Page 15 of 19		
Applicants: Gregory M Glenn <i>et al.</i> Filing Date: March 3, 2004		Group Art Unit: 1645

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
	Y1	3,964,482	06/1976	GERSTEL			
	Y2	4,775,361	10/1988	JACQUES			
	Y3	4,810,499	03/1989	NUWAYSER			
	Y4	5,003,987	04/1991	GRINWALD			
	Y5	5,133,970	07/1992	PETEREIT			
	Y6	5,182,109 C1	10/2001	TAMURA			
	Y7	5,250,023	10/1993	LEE			
	Y8	5,279,544	01/1994	GROSS			
	Y9	5,688,523	11/1997	GARBE			
	Y10	5,879,326	03/1999	GODSHALL			
	Y11	5,885,211	03/1999	EPPSTEIN			
	Y12	5,993,849	11/1999	ASSMUS			
	Y13	5,993,852	11/1999	FOLDVARI			
	Y14	6,019,982	02/2000	CLEMENTS			
	Y15	6,022,316	02/2000	EPPSTEIN			
	Y16	6,033,673	03/2000	CLEMENTS			
	Y17	6,033,684	03/2000	NORCIA			
	Y18	6,063,399	05/2000	ASSMUS			
	Y19	6,090,790	07/2000	ERIKSSON			
	Y20	6,142,939	11/2000	EPPSTEIN			
	Y21	6,149,919	11/2000	DOMENIGHINI			
	Y22	6,165,458	12/2000	FOLDVARI			
	Y23	6,165,500	12/2000	CEVC			
	Y24	6,190,367	02/2001	HALL			
	Y25	6,190,689	02/2001	HOFFMAN			
	Y26	6,207,184	03/2001	IKEDA			
	Y27	6,256,533	07/2001	YUZHAKOV			
	Y28	6,290,991	09/2001	ROSER			
	Y29	6,312,612	11/2001	SHERMAN			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes	No

OTHER DOCUMENTS

Examiner:	Date Considered:
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) PTO Form 1449	Attorney Docket No. 056707-5001-01	Parent Application No. 10/790,715
Applicants: Gregory M Glenn <i>et al.</i>		Page 16 of 19
Filing Date: March 3, 2004		Group Art Unit: 1645

U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
	Y30	6,331,266	12/2001	POWELL		
	Y31	6,331,310	12/2001	ROSER		
	Y32	6,334,856	01/2002	ALLEN		
	Y33	6,348,212	02/2002	HYMES		
	Y34	6,348,450	02/2002	TANG		
	Y35	6,365,178	04/2002	VENKATESHWARAN		
	Y36	6,379,324	04/2002	GARTSTEIN		
	Y37	6,406,705	06/2002	DAVIS		
	Y38	6,413,523	07/2002	CLEMENTS		
	Y39	6,440,096	08/2002	LASTOVICH		
	Y40	6,451,240	09/2002	SHERMAN		
	Y41	6,454,755	09/2002	GODSHALL		
	Y42	6,471,903	10/2002	SHERMAN		

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation Yes	Translation No
Y43	WO 95/17211	06/1995	WIPO			
Y44	WO 96/06627	03/1996	WIPO			
Y45	WO 96/19976	04/1996	WIPO			
Y46	WO 96/37256	11/1996	WIPO			
Y47	WO 97/04832	02/1997	WIPO			
Y48	WO 97/07734	03/1997	WIPO			
Y49	WO 98/00193	01/1998	WIPO			
Y50	WO 98/29134	07/1998	WIPO			
Y51	WO 99/13915	03/1999	WIPO			
Y52	WO 99/26662	06/1999	WIPO			
Y53	WO 99/47164	09/1999	WIPO			
Y54	WO 99/47165	09/1999	WIPO			
Y55	WO 99/47167	09/1999	WIPO			
Y56	WO 99/61078	12/1999	WIPO			
Y57	WO 00/33812	06/2000	WIPO			
Y58	WO 00/74714	12/2000	WIPO			

OTHER DOCUMENTS

Examiner:	Date Considered:
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) PTO Form 1449				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
				Page 17 of 19			
				Applicants: Gregory M Glenn <i>et al.</i> Filing Date: March 3, 2004		Group Art Unit: 1645	

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes No
	Y59	WO 00/74763	12/2000	WIPO			
	Y60	WO 00/74763 A3	12/2000	WIPO			
	Y61	WO 00/74766	12/2000	WIPO			
	Y62	WO 01/34185	05/2001	WIPO			
	Y63	WO 01/90758	11/2001	WIPO			
	Y64	WO 02/02179	01/2002	WIPO			
	Y65	WO 02/05889	01/2002	WIPO			
	Y66	WO 02/07813	01/2002	WIPO			
	Y67	WO 02/64162	08/2002	WIPO			
	Y68	WO 02/64193	08/2002	WIPO			
	Y69	WO 02/74244	09/2002	WIPO			

OTHER DOCUMENTS	
	Y70 BECKER "Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs) - A novel approach to the protection of human" Virus Genes 9 (1994) 33-45
	Y71 BECKER "An analysis of the role of skin Langerhans cells (LC) in the cytoplasmic processing of HIV-1 peptides after "peplotion" transepidermal transfer and HLA class I presentation to CD8+ CTLs - An approach to immunization of humans" Virus Genes 9 (1995) 133-147
	Y72 CASTLE "Clinical relevance of age-related immune dysfunction" Clin Infect Dis 31 (2000) 578-585
	Y73 CHEN "Adjuvation of epidermal powder immunization" Vaccine 19 (2001) 2908-2917
	Y74 CHEN "Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization" J Virol 75 (2001) 7956-7965
	Y75 EL-GHORR "Transcutaneous immunization with herpes simplex virus stimulates immunity in mice" FEMS Immunol Med Microbiol 29 (2000) 255-61
	Y76 FENG "P55, an immunogenic but nonprotective 55-kilodalton Borrelia burgdorferi protein in murine Lyme disease" Infect Immun 64 (1996) 363-365
Examiner: _____ Date Considered: _____	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) PTO Form 1449				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
				Page 18 of 19			
				Applicants: Gregory M Glenn <i>et al.</i> Filing Date: March 3, 2004		Group Art Unit: 1645	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes No
OTHER DOCUMENTS							
	Y77	GLUECK "Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine <i>Escherichia coli</i> heat-labile toxin as a mucosal adjuvant" J Infect Dis 181 (2000) 1129-1132					
	Y78	GOCKEL "Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract" Mol Immunol 37 (2000) 537-544					
	Y79	HAGIWAR "Effectiveness and safety of mutant <i>Escherichia coli</i> heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine" Vaccine 19 (2001) 2071-2079					
	Y80	HAGIWARA "Effects of intranasal administration of cholera toxin (or <i>Escherichia coli</i> heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain" 19 Vaccine (2001) 1652-1660					
	Y81	HIOE "Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides" Vaccine 14 (1996) 412-418					
	Y82	JANEWAY Immunobiology (1994) 10:78-10:79					
	Y83	KALBITZ "Modulation der wirkstoffpenetration in die haut" Pharmazie 51 (1996) 619-637					
	Y84	KATOH "Acute cutaneous barrier perturbation induces maturation of Langerhans' cells in hairless mice" Acta Derm Venereol 77(1997) 65-69					
	Y85	KUMAMOTO "Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine" Nat Biotechnol 20 (2002) 64-69					
	Y86	LIU "Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses" Vaccine 20 (2001) 42-48					
	Y87	LU "Mutant <i>Escherichia coli</i> heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine" Vaccine 20 (2002) 1019-1029					
	Y88	MURPHY "Antigen-Induced Protective and Nonprotective Cell-Mediated Immune Components against <i>Cryptococcus neoformans</i> " Infect Immun 66 (1998) 2632-2639					
Examiner:				Date Considered:			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) PTO Form 1449				Attorney Docket No. 056707-5001-01		Parent Application No. 10/790,715	
				Applicants: Gregory M Glenn <i>et al</i>		Page 19 of 19	
				Filing Date: March 3, 2004		Group Art Unit: 1645	

U.S. PATENT DOCUMENTS							
*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date	
	Y89	5,910,306	08/1999	Glenn			
	Y90	5,980,898	11/1999	Glenn			
	Y91	6,797,276	02/1999	Glenn			

FOREIGN PATENT DOCUMENTS							
Document Number	Date	Country	Class	Sub Class	Translation Yes No		
Y92	1061951	02/99	EP				

OTHER DOCUMENTS		
	Y93	OCKENHOUSE "Sequesterin, a CD36 recognition protein on <i>Plasmodium falciparum</i> malaria-infected erythrocytes identified by anti-idiotypic antibodies" Proc Natl Acad Sci 88 (1991) 3175-3179
	Y94	OGRA "Vaccination strategies for mucosal immune responses" Clin Microbiol Rev 14 (2001) 430-445
	Y95	PODDA "The adjuvanted influenza vaccines with novel adjuvants: Experience with the MF59-adjuvanted vaccine" Vaccine 19 (2001) 2673-2680
	Y96	WILLIAMS "Skin absorption enhancers" Critical Rev in Therapeutic Drug Carrier Systems 9 (1992) 305-353
	Y97	TAKIGAWA "Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis" Ann N Y Acad Sci 941 (2001) 139-146
	Y98	TANG "Vaccination onto bare skin" Nature 388 (1997) 729-730
	Y99	"Tuberculin, Purified protein Derivative, Tine Test" Physician's desk Reference, 3 pages (2001)
	Y100	WATABE "Protection against influenza virus challenge by topical application of influenza DNA vaccine" Vaccine 14 (2001) 4434-4444

Examiner:	Date Considered:
-----------	------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.